SudanTuberculosis profile
Population  2014 39 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 8.3 (4.3–14) 21 (11–34)
Mortality (HIV+TB only) 1 (0.67–1.4) 2.5 (1.7–3.6)
Prevalence  (includes HIV+TB) 59 (26–100) 151 (67–267)
Incidence  (includes HIV+TB) 37 (20–58) 94 (52–148)
Incidence (HIV+TB only) 1.2 (0.65–2) 3.2 (1.7–5.1)
         
Case detection, all forms (%) 52 (33–95)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.7 (0.3–3.1) 17 (4.4–30)
MDR-TB cases among notified pulmonary
TB cases
240 (42–440) 300 (78–530)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 6 106   655
Pulmonary, clinically diagnosed 7 934    
Extrapulmonary 4 571    
       
Total new and relapse 19 266    
Previously treated, excluding relapses 1 126    
Total cases notified 20 392    
Among 19 266 new cases:
2 152 (11%) cases aged under 15 years; male:female ratio: 1.6
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 24 (<1%) 103 (6%) 205
Laboratory-confirmed RR-/MDR-TB cases     82
Patients started on MDR-TB treatment ***     74
TB/HIV 2014 Number (%)
TB patients with known HIV status 5 501 (27)
HIV-positive TB patients 329 (6)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 147 (45)
HIV-positive people screened for TB 5 621  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (82) 17 396
Previously treated cases, excluding relapse, registered in 2013 (71) 514
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (62) 52
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 0.8
Culture (per 5 million population) 0.1
Drug susceptibility testing (per 5 million population) 0.1
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 12
% Funded domestically 20%
% Funded internationally 61%
% Unfunded 19%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-06 Data: www.who.int/tb/data